🇺🇸 FDA

Intelligence · Clinical Pipeline

Janssen-Cilag International N.V Pipeline

All ClinicalTrials.gov programs at Janssen-Cilag International N.V — phase, modality, and trial IDs.

Programs
54

Quick answer

Janssen-Cilag International N.V has 54 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. A Clinical Study to Assess the Safety, Tolerability of JNJ-63733657 and to evaluate how fast and to what extent JNJ-63733657 reaches the bloodstream and is absorbed, modified and removed from the body when administered as a Subcutaneous Infusion Using a Syringe Pump and as an Intravenous Infusion in Healthy Adult Participants

    Janssen-Cilag International N.V.

    Alzheimer's Disease (Healthy Participants)

    phase 1 other active

    1 trial

  2. A Clinical Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

    Janssen-Cilag International N.V.

    Advanced Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  3. A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma

    Janssen-Cilag International N.V.

    multiple myeloma

    phase 1 other active

    1 trial

  4. A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  5. A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  6. A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors

    Janssen-Cilag International N.V.

    Metastatic Castration-Resistant Prostate Cancer

    phase 1 other active

    1 trial

  7. A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer

    phase 1 other active

    1 trial

  8. A Phase 1 Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors

    Janssen-Cilag International N.V.

    Advanced Stage Solid Tumors

    phase 1 other active

    1 trial

  9. A Phase 1 Study of JNJ-87189401 Combined with JNJ-78278343 for Advanced Prostate Cancer

    Janssen-Cilag International N.V.

    Advanced Prostate Cancer

    phase 1 other active

    1 trial

  10. A Phase 1 Study of JNJ-87562761 in Relapsed/Refractory Multiple Myeloma

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  11. A Phase 1 Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers

    Janssen-Cilag International N.V.

    Non-Hodgkin Lymphoid Malignancies

    phase 1 other active

    1 trial

  12. A Phase 1 Study of JNJ-87890387 for Advanced Solid Tumors

    Janssen-Cilag International N.V.

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  13. A Phase 1 Study of JNJ-88549968, a T-cell Redirecting Antibody, for CALR-mutated Myeloproliferative Neoplasms

    Janssen-Cilag International N.V.

    CALR-mutated Myeloproliferative Neoplasms

    phase 1 other active

    1 trial

  14. A Phase 1 Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

    Janssen-Cilag International N.V.

    Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Types of Myelodysplastic Neoplasms

    phase 1 other active

    1 trial

  15. A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors.

    Janssen-Cilag International N.V.

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  16. A Phase 1 study of JNJ-95437446 in participants with advanced-stage solid tumors

    Janssen-Cilag International N.V.

    Locally advanced, metastatic NSCLC, CRC, or HNSCC that has recurred or progressed after prior stand of care therapy

    phase 1 other active

    1 trial

  17. A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants with Relapsed/Refractory B-cell NHL

    Janssen-Cilag International N.V.

    relapsed or refractory B‑cell non-Hodgkin lymphomas

    phase 1 other active

    1 trial

  18. A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

    Janssen-Cilag International N.V.

    Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Types of Myelodysplastic Neoplasms

    phase 1 other active

    1 trial

  19. A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and CLL

    Janssen-Cilag International N.V.

    Relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

    phase 1 other active

    1 trial

  20. A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL

    Janssen-Cilag International N.V.

    Non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  21. A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Amivantamab (JNJ61186372), a Human Bispecific EGFR and cMet Antibody, in Participants with Advanced Non-Small Cell Lung Cancer

    Janssen-Cilag International N.V.

    Advanced Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  22. A Phase 1, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Participants with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

    Janssen-Cilag International N.V.

    non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  23. A Phase 1, Open-label, Randomized, Crossover Study to Assess the Effect of Different Types of Co-administered Oral Liquids on the Relative Oral Bioavailability of a JNJ 77242113 Tablet Formulation in Healthy Participants.

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  24. A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  25. A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with either JNJ-63723283 (cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

    Janssen-Cilag International N.V.

    Metastatic Prostate Cancer

    phase 1 other active

    1 trial

  26. A Phase 1b Study of JNJ-79635322 with Daratumumab With or Without Lenalidomide or JNJ-79635322 with Pomalidomide for Multiple Myeloma

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 1 other active

    1 trial

  27. A Phase 1b Study of JNJ-80948543 in Combination with Other CD3 TCEs for R/R B-cell NHL

    Janssen-Cilag International N.V.

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies

    phase 1 other active

    1 trial

  28. A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma

    Janssen-Cilag International N.V.

    Multiple myeloma

    phase 1 other active

    1 trial

  29. A Phase 1b Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in Relapsed or Refractory B cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

    Janssen-Cilag International N.V.

    Non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  30. A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination with JNJ-67856633 in Participants with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

    Janssen-Cilag International N.V.

    non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  31. A Phase 1b/2 Study of JNJ-90014496 in Adult Participants with B-cell Non-Hodgkin Lymphoma

    Janssen-Cilag International N.V.

    Non-Hodgkin Lymphoid Malignancies

    phase 1 other active

    1 trial

  32. A Single Ascending Dose, Single-Centre Study, to Assess Pharmacokinetics, Safety and Tolerability of a Single Intramuscular Dose of Bedaquiline Long-Acting Injection Formulation in Healthy Participants

    Janssen-Cilag International N.V.

    Tuberculosis

    phase 1 other active

    1 trial

  33. A Study of JNJ-90301900 in Combination with Concurrent Chemoradiation Therapy in LA HNSCC

    Janssen-Cilag International N.V.

    Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

    phase 1 other active

    1 trial

  34. A study in healthy volunteers to find out how long aticaprant stays in and acts on the body when administered with or without food and with or without fluconazole

    Janssen-Cilag International N.V.

    Healthy Adult Participants

    phase 1 other active

    1 trial

  35. A study in healthy volunteers to find out how long aticaprant stays in and acts on the body when administered with or without rabeprazole.

    Janssen-Cilag International N.V.

    Healthy Adult Participants.

    phase 1 other active

    1 trial

  36. A study to assess the effect of single and repeated doses of JNJ-81241459 on a single dose of certain other drugs, when given together to healthy adult participants

    Janssen-Cilag International N.V.

    Plaque Psoriasis

    phase 1 other active

    1 trial

  37. A study to compare how the body absorbs different formulations of a new medicine, and how food affects drug absorption, in healthy participants

    Janssen-Cilag International N.V.

    Psoriasis

    phase 1 other active

    1 trial

  38. A study to compare the amount of milvexian in blood when given as pediatric and adult tablet formulations, to assess the effect of food intake on the absorption of pediatric milvexian tablet formulation in healthy adult participants and to assess the acceptability of different milvexian formulations.

    Janssen-Cilag International N.V.

    atherothrombotic and thromboembolic disorders

    phase 1 other active

    1 trial

  39. A study to evaluate how the body absorbs, breaks down and removes drug as well as safety and tolerability when two drugs are administered together as an injection under the skin to healthy participants.

    Janssen-Cilag International N.V.

    Healthy Volunteers

    phase 1 other active

    1 trial

  40. A study to evaluate the safety and tolerability of JNJ-70035108 and to evaluate how long JNJ-70035108 stays in and acts on the body (pharmacokinetics) when given as single and repeated doses to healthy participants

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  41. A study to evaluate the safety and tolerability of JNJ-90106848 and to investigate how long JNJ-90106848 stays in and acts on the body (pharmacokinetics) and how the body responds to JNJ-90106848 (pharmacodynamics) when injected into healthy volunteer participants

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  42. A study to investigate the safety, the amount that reaches the bloodstream and the effects on the body of JNJ-64619178 in people with advanced cancers

    Janssen-Cilag International N.V.

    Previously treated lymphoma (blood cancer) or solid tumors and NHL

    phase 1 other active

    1 trial

  43. A three-part trial in healthy volunteers to find out how long icotrokinra stays in and acts on the body when administered as different tablet formulations and under different food conditions

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  44. A two-part trial in healthy volunteers to find out how long JNJ-77242113 stays in and acts on the body when administered as different tablet formulations and under different food and water conditions, and to assess the acceptability profile (taste, palatability, and smell) of JNJ-77242113 formulations.

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial

  45. An Open-Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring

    Janssen-Cilag International N.V.

    Non-Hodgkin lymphoma and chronic lymphocytic leukemia

    phase 1 other active

    1 trial

  46. An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-77242113 in Adult Participants

    Janssen-Cilag International N.V.

    Renal Impairment

    phase 1 other active

    1 trial

  47. Characterization of Immune Response in Participants from a Posdinemab Study

    Janssen-Cilag International N.V.

    Early Alzheimer's disease

    phase 1 other active

    1 trial

  48. Citarabina Hikma 2 g/20mL Soluzione Iniettabile, Idarubicin Hikma 1 mg/ml Injektionslösung, Cytarabine 100 mg/ml Solution for Injection or Infusion, Cytarabine 100 mg/ml Solution for Injection or Infusion, Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung, JNJ-75276617, JNJ-75276617 (G022), Venclyxto 100 mg film-coated tablets, Idarubicin, Venclyxto 100 mg film-coated tablets, JNJ-75276617, JNJ-75276617 (G023), Azacitidine, JNJ-75276617, Citarabina Hikma 500mg/5mL Soluzione I

    Janssen-Cilag International N.V.

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Janssen-Cilag International N.V have?

54 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.